000061470 001__ 61470
000061470 005__ 20200221144336.0
000061470 0247_ $$2doi$$a10.3748/wjg.v22.i28.6501
000061470 0248_ $$2sideral$$a96067
000061470 037__ $$aART-2016-96067
000061470 041__ $$aeng
000061470 100__ $$aPasut, G.
000061470 245__ $$aPolyethylene glycols: An effective strategy for limiting liver ischemia reperfusion injury
000061470 260__ $$c2016
000061470 5060_ $$aAccess copy available to the general public$$fUnrestricted
000061470 5203_ $$aLiver ischemia-reperfusion injury (IRI) is an inherent feature of liver surgery and liver transplantation in which damage to a hypoxic organ (ischemia) is exacerbated following the return of oxygen delivery (reperfusion). IRI is a major cause of primary non-function after transplantation and may lead to graft rejection, regardless of immunological considerations. The immediate response involves the disruption of cellular mitochondrial oxidative phosphorylation and the accumulation of metabolic intermediates during the ischemic period, and oxidative stress during blood flow restoration. Moreover, a complex cascade of inflammatory mediators is generated during reperfusion, contributing to the extension of the damage and finally to organ failure. A variety of pharmacological interventions (antioxidants, anti-cytokines, etc.) have been proposed to alleviate graft injury but their usefulness is limited by the local and specific action of the drugs and by their potential undesirable toxic effects. Polyethylene glycols (PEGs), which are non-toxic water-soluble compounds approved by the FDA, have been widely used as a vehicle or a base in food, cosmetics and pharmaceuticals, and also as adjuvants for ameliorating drug pharmacokinetics. Some PEGs are also currently used as additives in organ preservation solutions prior to transplantation in order to limit the damage associated with cold ischemia reperfusion. More recently, the administration of PEGs of different molecular weights by intravenous injection has emerged as a new therapeutic tool to protect liver grafts from IRI. In this review, we summarize the current knowledge concerning the use of PEGs as a useful target for limiting liver IRI.
000061470 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000061470 590__ $$a3.365$$b2016
000061470 591__ $$aGASTROENTEROLOGY & HEPATOLOGY$$b29 / 79 = 0.367$$c2016$$dQ2$$eT2
000061470 592__ $$a1.272$$b2016
000061470 593__ $$aMedicine (miscellaneous)$$c2016$$dQ1
000061470 593__ $$aGastroenterology$$c2016$$dQ1
000061470 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000061470 700__ $$aPanisello, A.
000061470 700__ $$aFolch-Puy, E.
000061470 700__ $$aLopez, A.
000061470 700__ $$aCastro-Benítez, C.
000061470 700__ $$aCalvo, M.
000061470 700__ $$aCarbonell, T.
000061470 700__ $$0(orcid)0000-0002-8275-7191$$aGarcía-Gil, A.$$uUniversidad de Zaragoza
000061470 700__ $$aAdam, R.
000061470 700__ $$aRoselló-Catafau, J.
000061470 7102_ $$11004$$2090$$aUniversidad de Zaragoza$$bDpto. Cirugía,Ginecol.Obstetr.$$cÁrea Cirugía
000061470 773__ $$g22, 28 (2016), 6501-6508$$tWORLD JOURNAL OF GASTROENTEROLOGY$$x1007-9327
000061470 8564_ $$s1453316$$uhttps://zaguan.unizar.es/record/61470/files/texto_completo.pdf$$yVersión publicada
000061470 8564_ $$s110374$$uhttps://zaguan.unizar.es/record/61470/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000061470 909CO $$ooai:zaguan.unizar.es:61470$$particulos$$pdriver
000061470 951__ $$a2020-02-21-13:47:13
000061470 980__ $$aARTICLE